Fundraising Fox

Inflammatix

Burlingame, US · Founded 2016 · Delaware corporation · 72 employees on LinkedIn · 4 known investors

Inflammatix develops host-response-based molecular diagnostics tests to identify acute infections and sepsis in emergency and critical care settings. The company's diagnostic platform serves healthcare providers treating acutely ill patients, with applications extending to emerging infectious diseases, autoimmune conditions, and transplant rejection.

AI & Machine LearningBiotechHealthtechMedical Devices

Founders & leadership

Inflammatix was founded in 2016 by Tim Sweeney and Purvesh Khatri.

TSTim Sweeney
Tim SweeneyCo-Founder and CEO
PKPurvesh Khatri
Purvesh KhatriCo-Founder and Chief Scientist
JR
JONATHAN ROMANOWSKYExecutive

Board

KB
KENNETH BAHKBoard director
MR
MICHAEL RUBINBoard director
DP
DAVID PERSINGBoard director
ST
STEVEN TABLAKBoard director

Investors · 4

Khosla Ventures✓ verifiedMenlo Park · $5K – $50M
Northpond Ventures✓ verifiedBethesda · $100K – $5M
OSF VenturesPeoria
DFJreportedSan Mateovia Justin Kao · board

Reported raises · per SEC filings

Form D private placements

$134.5M disclosed across 2 of 3 rounds · 2020–2024

▶$102.4MraisedMar 2021 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • MICHAEL RUBINDirector
  • JUSTIN KAODirector
  • KENNETH BAHKDirector
  • TIMOTHY SWEENEYExecutive Officer, Director
  • STEVEN TABLAKDirector
  • DAVID PERSINGDirector
Offering amount
$102.4M
Amount sold
$102.4M
First sale
Mar 2021
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$32.1MraisedFeb 2020 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • TIMOTHY SWEENEYExecutive Officer, Director
  • JONATHAN ROMANOWSKYExecutive Officer
  • KENNETH BAHKDirector
  • DAVID PERSINGDirector
  • STEVEN TABLAKDirector
  • MICHAEL RUBINDirector
Offering amount
$32.1M
Amount sold
$32.1M
First sale
Jan 2020
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Bioworld7 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Inflammatix for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$299.8K
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$1.7M
National Institutes of Health (NIH)National Institutes of HealthPhase I2021$251.4K
Defense Advanced Research Projects Agency (DARPA)Defense Advanced Research Projects AgencyPhase II2017$999.9K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Inflammatix Raises $57M for its Acute Infection and Sepsis Testfinance.yahoo.com · Sep 2024Inflammatix Secures $57 Million to Advance Novel Diagnostic for Patients with Suspected Infections or Sepsisprnewswire.com · Sep 2024Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics - Inflammatixinflammatix.com · Mar 2021Inflammatix nets $102M to advance its immune system tests for infectious diseases | Fierce Biotechfiercebiotech.com · Mar 2021Inflammatix Raises $102M in Series D Financing to Continue Development of Immune-Response Tests | 360Dx360dx.com · Mar 2021Inflammatix Announces $32 Million in Series C Funding - Inflammatixinflammatix.com · Jan 2020

Frequently asked questions

What does Inflammatix do?
Inflammatix develops host-response-based molecular diagnostics tests to identify acute infections and sepsis in emergency and critical care settings. The company's diagnostic platform serves healthcare providers treating acutely ill patients, with applications extending to emerging infectious diseases, autoimmune conditions, and transplant rejection.
Who founded Inflammatix?
Inflammatix was founded by Tim Sweeney, Purvesh Khatri in 2016.
Who are Inflammatix's investors?
Inflammatix's investors include Khosla Ventures, Northpond Ventures, OSF Ventures, DFJ.
How much funding has Inflammatix raised?
Inflammatix has disclosed $134.5M raised across 2 of its 3 known rounds.
Where is Inflammatix headquartered?
Inflammatix is headquartered in Burlingame, US.